Faes Farma, S.A. (LON:0K9H)
United Kingdom · Delayed Price · Currency is GBP · Price in EUR | Market Cap | 1.28B +6.4% |
| Revenue (ttm) | 630.00M +29.0% |
| Net Income | 68.60M -23.7% |
| EPS | 0.21 |
| Shares Out | n/a |
| PE Ratio | 19.16 |
| Forward PE | 14.75 |
| Dividend | 0.09 (2.18%) |
| Ex-Dividend Date | Jul 2, 2026 |
| Volume | 5,985 |
| Open | 4.910 |
| Previous Close | 4.930 |
| Day's Range | 4.865 - 4.950 |
| 52-Week Range | 4.325 - 5.480 |
| Beta | 0.30 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 29, 2026 |
About Faes Farma
Faes Farma, S.A., researches, develops, produces, and markets pharmaceutical products, healthcare products, and raw materials internationally. The company operates through Pharmaceutical and Healthcare Specialties; Animal Nutrition and Health; and Pharmaceutical Raw Materials segments. It engages in chemical and pharmaceutical products, foodstuffs, cosmetics, dietetics and medicinal plants services, as well as acquiring, purchasing, disposing of, investing in, holding, using, managing, administering, marketing and leasing corporations, securiti... [Read more]
Financial Performance
In 2025, Faes Farma's revenue was 626.99 million, an increase of 22.93% compared to the previous year's 510.04 million. Earnings were 79.63 million, a decrease of -28.49%.
Financial numbers in EUR Financial StatementsNews
Faes Farma Earnings Call Transcript: Q3 2026
9M revenue increased 24% and EBITDA 17%, or 20% excluding restructuring costs, with FY26 guidance reaffirmed. International growth and SIFI integration offset Japan bilastine losses; cash generation accelerated and net debt was ~€260 million.
Faes Farma Slides: Q3 2026
Faes Farma has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 29, 2026.
Faes Farma Earnings release: Q3 2026
Faes Farma released its Q3 2026 earnings on October 29, 2026, summarizing the period's financial results.
Faes Farma Earnings Call Transcript: Q2 2026
Revenue grew 27% year-over-year to EUR 391.5 million, with EBITDA up 24% and net income up 9%. Integration of SIFI and Edol boosted ophthalmology, now 16% of revenue. Guidance for 2026 reaffirmed, with strong international and LATAM growth expected.
Faes Farma Slides: Q2 2026
Faes Farma has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 30, 2026.
Faes Farma Earnings release: Q2 2026
Faes Farma released its Q2 2026 earnings on July 30, 2026, summarizing the period's financial results.
Faes Farma Quarterly report: Q2 2026
Faes Farma has published its Q2 2026 quarterly earnings report on July 30, 2026.
Faes Farma Earnings Call Transcript: Q1 2026
Revenue grew 31% year-over-year to EUR 200.1 million, with strong organic and acquisition-driven growth. Net profit rose 9%, and guidance for 2026 is maintained despite expected headwinds from Bilastine generics in Japan.
Faes Farma Slides: Q1 2026
Faes Farma has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 30, 2026.
Faes Farma Earnings release: Q1 2026
Faes Farma released its Q1 2026 earnings on April 30, 2026, summarizing the period's financial results.
Faes Farma Earnings Call Transcript: Q4 2025
2025 saw 23% revenue growth, major acquisitions, and strong international expansion, with adjusted EBITDA up 3.1% and net profit down due to one-offs. 2026 guidance targets 17%-19% revenue and 28%-31% EBITDA growth, with continued focus on integration, efficiency, and international markets.
Faes Farma Earnings release: Q4 2025
Faes Farma released its Q4 2025 earnings on February 26, 2026, summarizing the period's financial results.
Faes Farma Slides: Q4 2025
Faes Farma has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 26, 2026.
Faes Farma Annual report: Q4 2025
Faes Farma has published its Q4 2025 annual report on February 26, 2026.